Inizio Ignite Sparks a New Era of Connected Advisory Solutions
January 7, 2026 | Inizio Ignite
Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.
Inizio Ignite brings together Research Partnership, Putnam, Vynamic, and STEM to address the growing complexity of today’s pharmaceutical environment. Purpose-built and AI-enabled, Inizio Ignite helps clients shape strategy, drive scalable transformation, and deliver measurable impact uniting connected expertise and advanced technology platforms into a single advisory solution designed to deliver greater impact for clients and the patients they serve.
Inizio Ignite operates as part of Inizio’s broader global commercialization platform, enabling clients to seamlessly access deep, cross-functional expertise across the entire product lifecycle. With more than 10,500 experts in over 50 countries, Inizio brings together scientific, medical, commercial, analytics, and technology capabilities to help clients solve complex challenges in a flexible, client-centred way – from strategy through execution.
Focused exclusively on life sciences and healthcare, Inizio Ignite integrates Inizio’s former Advisory capabilities to create one of the largest and most specialized advisory partners in the sector. With more than 1,000 experts, including 100 PhD, PharmD, and MDs across more than 50 countries, Inizio Ignite advises clients across more than 20 therapy and disease areas and has partnered on 1,100 assets with all top 20 pharmaceutical companies. Across the product lifecycle, from early development through post-launch, Inizio Ignite supports data-driven portfolio and launch strategies, embeds advanced analytics, and translates insight into execution – delivering Intelligent Commercialization™ as part of Inizio’s end-to-end platform.
Remco op den Kelder, Global President of Inizio Ignite, said:
“By uniting our teams, we’re creating something new – an integrated partner bringing together the insight, strategy, and transformation support that pharma companies need to win in today’s market. This evolution represents a meaningful shift in how we serve our clients, delivering clearer answers, stronger guidance, and faster impact for the patients who rely on them.”
“With a seamlessly connected team, clients benefit from deeper expertise and broader capabilities at every stage of their journey. This transformation strengthens our ability to drive innovation at scale, pairing clarity and precision with the speed required to turn strategy into real-world impact. It positions us to advance the next generation of treatments and to help shape the future of human health.”
Find out more about Inizio Ignite and its solutions here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Device Attribute Testing
Our client wanted to determine the optimal new blood glucose monitoring device – one that would best retain their current customers and also attract new ones. They also wanted to...
Research Partnership welcomes 20 new Graduates
This year we are celebrating 20 years in business and as part of our continued growth, we are delighted to announce a new intake of 17 Research Analysts and 3...
Corporate Equity Survey
Our client’s senior management wanted to assess its company’s image amongst their key HCP stakeholders. The client wanted to measure familiarity and perceptions of the company versus its competitors, particularly...
Webcast: Capturing the “moments-of-truth” using online communities and bulletin boards
MROCs and bulletin boards are growing in popularity because they offer specific benefits over or alongside more traditional methodologies – providing the opportunity to create a panel of geographically disperse...
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017
Living with Ulcerative Colitis (UC) is a study conducted amongst 110 adult UC patients in the US. The study employs a mixed quantitative/qualitative methodology and is available to purchase alongside...
20 questions: Round 5
As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month we asked our US employees about office life in Philadelphia.Watch the video: https://www.researchpartnership.com/news/2017/08/20-questions-round-5/
Research Partnership publishes 2017 Living with NASH report
Healthcare market research and consultancy specialist Research Partnership has published a new Living with Non-alcoholic Steatohepatitis (NASH) report for 2017.Living with Non-alcoholic Steatohepatitis (NASH) is a quantitative US study conducted online amongst patients....
Blending qual and quant – the benefits of a hybrid approach
My colleague Chris Gaj and I recently conducted a video dialogue on the topic of hybrid qual/quant methods in which we discussed why clients often want to blend the two, and the...
Multi-level Segmentation Solution
Our client has an established product for multiple indications. They wanted to create a HCP segmentation typing tool which could be implemented in-field to help classify physicians across two different...
Global health care specialists from coast to coast
Published in Quirk's Faces of Marketing Research August 2017